https://www.thebodypro.com/category/hiv-treatments-in-development
HIV Treatment Strategies

HIV Treatments in Development

The Latest

Phase 3 Results With Bictegravir -- A New Integrase Inhibitor Combined With FTC/TAF Img
IAS (International AIDS Society) Conference

Phase 3 Results With Bictegravir -- A New Integrase Inhibitor Combined With FTC/TAF

Two studies presented at IAS 2017 showed bictegravir to be very similar in efficacy to dolutegravir with slight differences in the formulations linked to the background NRTIs in the fixed-dose combinations.

HIV Remission News From IAS 2017 Img
IAS (International AIDS Society) Conference

HIV Remission News From IAS 2017

Treatment Action Group's Richard Jefferys provides a comprehensive overview of HIV remission presentations at the 9th International AIDS Society Conference on HIV Science.

The Future of 2-Drug Regimens for People With HIV Img
Features

The Future of 2-Drug Regimens for People With HIV

Reducing the number of drugs in a treatment regimen lowers long-term drug exposure and potential drug toxicity or drug interactions. What can we expect in the future for two-drug regimens?

Evidence of Smaller HIV Reservoirs in a Ugandan Cohort Img

Evidence of Smaller HIV Reservoirs in a Ugandan Cohort

Researchers found a higher set point viral load prior to antiretroviral treatment (ART) was associated with a larger HIV reservoir, while a longer duration of viral suppression due to ART was associated with a smaller reservoir.

Bictegravir/FTC/TAF: New Once-Daily Integrase-Based Fixed-Dose Combination Submitted to U.S. FDA Img

Bictegravir/FTC/TAF: New Once-Daily Integrase-Based Fixed-Dose Combination Submitted to U.S. FDA

Gilead Sciences has submitted a new drug application to the U.S. FDA for a single tablet fixed-dose combination of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).

Long-Acting Injectable Antiretrovirals for PrEP: Will the Tail Wag the Drug? Img

Long-Acting Injectable Antiretrovirals for PrEP: Will the Tail Wag the Drug?

A medicine you get only every two months to reduce your risk of acquiring HIV could be an option in the future, but only if two clinical trials show that it is safe and effective.

This Week in HIV Research: New Maturation Inhibitor May Work Against Protease Inhibitor-Resistant HIV Img

This Week in HIV Research: New Maturation Inhibitor May Work Against Protease Inhibitor-Resistant HIV

This week, a study finds that a new maturation inhibitor in development, GSK3532795, shows activity against HIV that is resistant to protease inhibitors.

The Best HIV Cure Will Be Built With Us, Not Just for Us Img
CROI (Conference on Retroviruses and Opportunistic Infections)

The Best HIV Cure Will Be Built With Us, Not Just for Us

"Without early and consistent partnership with the community in our efforts to incrementally develop a cure for HIV we may never achieve what people with HIV most hope a cure will offer them."

Ibalizumab Is Effective at Reducing HIV Viral Load in People With Few Treatment Options Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Ibalizumab Is Effective at Reducing HIV Viral Load in People With Few Treatment Options

A study showed that a new monoclonal antibody drug called ibalizumab reduced viral loads in individuals with multi-drug resistant HIV. Adding the drug to a failing regimen may help treatment-experienced people who have few options to control their vi...

In the Vanguard of HIV Vaccine Research Img

In the Vanguard of HIV Vaccine Research

An interview with Dan Barouch, M.D., Ph.D., on the key challenges in vaccine development, the pursuit of vaccines to potentially cure HIV and why we should be excited about antibodies.